176 related articles for article (PubMed ID: 33624150)
1. EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshell.
Kunikowska J; Ambrosini V; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1276-1277. PubMed ID: 33624150
[No Abstract] [Full Text] [Related]
2. The EANM Focus 5 consensus on 'molecular imaging and theranostics in prostate cancer': the future begins today.
Oprea-Lager DE; MacLennan S; Dierckx R; Fanti S
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1462-1463. PubMed ID: 38280047
[No Abstract] [Full Text] [Related]
3. Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine.
Arora G; Bandopadhyaya G
Ann Nucl Med; 2018 Apr; 32(3):151-164. PubMed ID: 29374820
[TBL] [Abstract][Full Text] [Related]
4. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
5. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging and Theranostics in Pancreatic Neuroendocrine Tumours: From a Luminous Present to an Even Brighter Future.
Paola M; Mansi L
Curr Radiopharm; 2019; 12(2):93-95. PubMed ID: 31362647
[No Abstract] [Full Text] [Related]
7. EANM Focus 1: one small step for two men, one giant leap for a specialty.
Fanti S; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1400-1401. PubMed ID: 31016331
[No Abstract] [Full Text] [Related]
8. Diagnosis and therapy of neuroendocrine tumours.
Bombardieri E; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):1-2. PubMed ID: 20168281
[No Abstract] [Full Text] [Related]
9. Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine".
Aboagye EO; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1559-1574. PubMed ID: 28597119
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of nuclear medicine in haematological tumours-EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours.
Nanni C; Kobe C; Herrmann K; Kunikowska J
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2925-2926. PubMed ID: 37358621
[No Abstract] [Full Text] [Related]
11. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.
Van Weehaeghe D; Lapauw B; Fraioli F; Cecchin D; Verger A; Guedj E; Albert NL; Brendel M; Yakushev I; Barthel H; Traub-Weidinger T; Tolboom N; Giessen EV
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2367-2370. PubMed ID: 38687371
[No Abstract] [Full Text] [Related]
12. 2016 SNMMI Highlights Lecture: Oncology, Part 1.
Weber WA
J Nucl Med; 2017 Jan; 58(1):9N-15N. PubMed ID: 28062717
[No Abstract] [Full Text] [Related]
13. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.
Herrmann K; Giovanella L; Santos A; Gear J; Kiratli PO; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2300-2309. PubMed ID: 35403861
[TBL] [Abstract][Full Text] [Related]
14. Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging.
Minutoli F; Laudicella R; Burger IA; Baldari S
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3041-3042. PubMed ID: 33851244
[No Abstract] [Full Text] [Related]
15. EANM position paper: theranostics in brain tumours-the present and the future.
Tolboom N; Verger A; Albert NL; Brendel M; Cecchin D; Fernandez PA; Fraioli F; Guedj E; Herrmann K; Traub-Weidinger T; Morbelli S; Yakushev I; Zucchetta P; Barthel H; Van Weehaeghe D
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):202-205. PubMed ID: 37698647
[No Abstract] [Full Text] [Related]
16. Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
Herrmann K; Giovanella L; Santos A; Gear J; Ozgen Kiratli P; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
J Nucl Med; 2022 Dec; 63(12):1836-1843. PubMed ID: 35450957
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.
Czernin J; Calais J
J Nucl Med Technol; 2020 Jun; 48(Suppl 1):82S-83S. PubMed ID: 32605963
[No Abstract] [Full Text] [Related]
18. PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors.
Pinho DF; Subramaniam RM
PET Clin; 2017 Oct; 12(4):407-421. PubMed ID: 28867112
[No Abstract] [Full Text] [Related]
19. How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation.
Ambrosini V; Carrilho Vaz S; Ahmadi Bidakhvidi N; Chanchou M; Cysouw MCF; Serani F; Voltin CA; Kraeber-Bodere F; Deroose CM; De Geus-Oei LF; Eiber M; Gnanasegaran G; Gotthardt M; Kobe C; Konijnenberg MW; Nanni C; Oprea Lager DE; Rahbar K; Taieb D; Mottaghy FM; Goffin K; Herrmann K
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):3-11. PubMed ID: 37689611
[No Abstract] [Full Text] [Related]
20. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
